Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $7.7 million.

  • bioAffinity Technologies' Cash & Equivalents rose 86250.0% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year increase of 86250.0%. This contributed to the annual value of $1.1 million for FY2024, which is 6082.71% down from last year.
  • Per bioAffinity Technologies' latest filing, its Cash & Equivalents stood at $7.7 million for Q3 2025, which was up 86250.0% from $802835.0 recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Cash & Equivalents high stood at $13.5 million for Q3 2022, and its period low was $444706.0 during Q1 2025.
  • Its 4-year average for Cash & Equivalents is $5.0 million, with a median of $2.8 million in 2023.
  • Per our database at Business Quant, bioAffinity Technologies' Cash & Equivalents tumbled by 9034.57% in 2024 and then skyrocketed by 86250.0% in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Cash & Equivalents stood at $11.4 million in 2022, then plummeted by 75.28% to $2.8 million in 2023, then crashed by 60.83% to $1.1 million in 2024, then soared by 596.65% to $7.7 million in 2025.
  • Its Cash & Equivalents was $7.7 million in Q3 2025, compared to $802835.0 in Q2 2025 and $444706.0 in Q1 2025.